Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients

Shimoyama, Naohito; Shimoyama, Megumi

doi:10.1016/s0885-3924(01)00367-0

Cited by 63 publications

(33 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies performed using inhaled furosemide have been small and uncontrolled, but results have been positive. [13,14] Wilcock et al (2008) conducted a randomized controlled study and reported that nebulized furosemide had no impact on dyspnea with cancer patients and did not cause any side effects. [15] Despite participants stating that they felt relief from the dyspnea, there were no statistically significant results in another randomized controlled trial examining the effect of nebulized furosemide in the management of cancer-related dyspnea.…”

Section: Diureticsmentioning

confidence: 99%

Dyspnea Management in Patients with Cancer

Metin¹

2016

TJ Oncol

View full text Add to dashboard Cite

SUMMARYDyspnea in patients with cancer is a common symptom and is generally associated with anxiety. It limits patients' activities of daily living and adversely affects not only patients, but also caregivers. It remains a difficult symptom to manage, despite recent advances in cancer treatment and the increasing evidence available. Different pharmacological approaches such as opioids, and nonpharmacological interventions including oxygen, fun, exercise, pulmonary rehabilitation, acupuncture, acupressure and cognitive-behavioral therapies are used to manage dyspnea. Symptom management and supportive therapies given by oncology nurses become important in patients with cancer who experience dyspnea. There are limited number of publications about the management of dyspnea in Turkish oncology nursing literature. This literature review aims to inform nurses about cancer patients with dyspnea.

show abstract

Section: Diureticsmentioning

confidence: 99%

Dyspnea Management in Patients with Cancer

Metin¹

2016

TJ Oncol

View full text Add to dashboard Cite

show abstract

“…This finding led to inhaled furosemide being evaluated in cancer patients. A group of three cancer patients reported improved dyspnea when given nebulised furosemide (20 mg) (Shimoyama et al, 2002). Nebulisation of a bronchodilator before giving inhaled furosemide had no effect and the authors excluded a placebo effect.…”

Section: Furosemidementioning

confidence: 99%

The Airways: A Promising Route for the Pulmonary Delivery of Anticancer Agents

Guilleminault¹,

Hervé-Grépinet²,

Lemarié³

et al. 2011

Advances in Cancer Therapy

View full text Add to dashboard Cite

“…In an uncontrolled study in patients with endstage cancer, Shimoyama and Shimoyama [ 55 ] reported on three patients whose dyspnea, refractory to opioids, dramatically improved for weeks with 20 mg of inhaled furosemide four times a day, with individual treatment effects lasting for up to 4 hours. In controlled experimental settings with volunteers, furosemide decreased dyspnea generated by breathholding, hypercapnia, and hypercapnia together with increased work of breathing [ 56 , 57 , 58• ].…”

Section: Inhaled Furosemidementioning

confidence: 99%

The symptomatic relief of dyspnea

Elia¹,

Thomas

2008

Curr Oncol Rep

View full text Add to dashboard Cite

Dyspnea is a common symptom that causes considerable suffering in cancer patients. Although some knowledge of the sensory information that is transduced to the brain during dyspnea exists, we still have only a rudimentary understanding of the subjective perception of this symptom. There appear to be many parallels between pain and dyspnea. Consistent with this fact, there is growing evidence that opioids are safe and effective and should be considered front-line therapy for symptomatic relief of dyspnea. In addition to opioids, there are other important pharmacologic and nonpharmacologic tools with varying degrees of support that can be considered for symptomatic relief. Importantly, because dyspnea is a subjective symptom that occurs in a unique individual, the optimal treatment of dyspnea will always entail an understanding of, and support for, a patient's other sources of psychosocial, spiritual, and/or existential suffering.

show abstract

Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients

Cited by 63 publications

References 13 publications

Dyspnea Management in Patients with Cancer

Dyspnea Management in Patients with Cancer

The Airways: A Promising Route for the Pulmonary Delivery of Anticancer Agents

The symptomatic relief of dyspnea

Contact Info

Product

Resources

About